Iovance Biotherapeutics, Inc.
IOVA
$2.83
$0.155.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -33.07% | 25.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -33.07% | 25.85% | |||
| Cost of Revenue | 9.22% | 14.36% | |||
| Gross Profit | -101.48% | 50.28% | |||
| SG&A Expenses | 3.35% | 7.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.41% | 8.57% | |||
| Operating Income | -40.02% | 2.80% | |||
| Income Before Tax | -53.25% | 9.48% | |||
| Income Tax Expenses | -217.97% | 202.50% | |||
| Earnings from Continuing Operations | -47.87% | 5.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -47.87% | 5.96% | |||
| EBIT | -40.02% | 2.80% | |||
| EBITDA | -44.80% | 3.04% | |||
| EPS Basic | -39.62% | 6.46% | |||
| Normalized Basic EPS | -42.26% | 6.73% | |||
| EPS Diluted | -39.62% | 6.46% | |||
| Normalized Diluted EPS | -42.26% | 6.73% | |||
| Average Basic Shares Outstanding | 5.90% | 0.53% | |||
| Average Diluted Shares Outstanding | 5.90% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||